Cambridge Antibody Technology Group Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Cambridge Antibody Technology Group

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: nigel bates who wrote (366)	5/29/2003 9:35:20 AM
From: tuck	Read Replies (2) of 625

>>NEW YORK, May 29 (Reuters) - Abbott Laboratories Inc. (NYSE:ABT - News) said on Thursday it expects sales of its rheumatoid arthritis drug, Humira, to be higher than it originally expected. Miles White, the company's chief executive, told analysts at a meeting in New York that he now expects Humira sales to be more than $250 million this year, compared to a previous estimate of $200 million. The drug, which analysts have said is likely to be the most important product in Abbott's portfolio over the next five years, will likely generate sales of $500 million in 2004, White said, in line with his previous estimate. Eventually, White said he expects Humira could be a "multibillion dollar" product.<< Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next